CD44 and cancer: Thereby, cultured circulating melanoma-derived cancer hybrid cells concomitantly expressed macrophage markers (CD14, CD68, CD163, CD204, and CD206), melanocyte-specific markers (ALCAM, MLANA, and melanoma-specific BRAFV600E mutations), epithelial cell markers (CK, EpCAM), and some stem cell-related markers (CXCR4, CD44) [192].